LYSET

Summary

LYSET (lysosomal enzyme trafficking factor, HGNC:20218) is a protein-coding gene on chromosome 14q32.12, encoding Lysosomal enzyme trafficking factor (Q8N6I4). Required for mannose-6-phosphate-dependent trafficking of lysosomal enzymes.

Involved in lysosomal transport; lysosome organization; and regulation of vesicle-mediated transport. Located in Golgi cisterna.

Source: NCBI Gene 26175 — RefSeq curated summary.

At a glance

• Gene–disease (curated): dysostosis multiplex, Ain-Naz type (Strong, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 30 total — 1 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_001098621

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20218
Approved symbol	LYSET
Name	lysosomal enzyme trafficking factor
Location	14q32.12
Locus type	gene with protein product
Status	Approved
Aliases	DKFZP564F1123, GCAF
Ensembl gene	ENSG00000153485
Ensembl biotype	protein_coding
OMIM	619332
Entrez	26175

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000283534, ENST00000415050, ENST00000857222, ENST00000928792, ENST00000928793, ENST00000928794

RefSeq mRNA: 2 — MANE Select: NM_001098621 NM_001098621, NM_015676

CCDS: CCDS41980, CCDS45158

Canonical transcript exons

ENST00000415050 — 2 exons

Exon	Start	End
ENSE00001687352	93186260	93188463
ENSE00001745397	93185317	93185485

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 93.31.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.4689 / max 482.8426, expressed in 1777 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
141163	9.1972	1770
141167	4.3490	520
141165	0.3243	137
141166	0.3104	137
141168	0.2881	97

Top tissues by expression

137 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
islet of Langerhans	UBERON:0000006	93.31	gold quality
mucosa of transverse colon	UBERON:0004991	92.19	gold quality
rectum	UBERON:0001052	90.57	gold quality
endometrium	UBERON:0001295	90.14	gold quality
monocyte	CL:0000576	89.99	gold quality
adult mammalian kidney	UBERON:0000082	89.93	gold quality
ventricular zone	UBERON:0003053	89.93	gold quality
leukocyte	CL:0000738	89.90	gold quality
apex of heart	UBERON:0002098	89.65	gold quality
gastrocnemius	UBERON:0001388	89.52	gold quality
right adrenal gland cortex	UBERON:0035827	89.52	gold quality
pancreas	UBERON:0001264	89.27	gold quality
right adrenal gland	UBERON:0001233	89.26	gold quality
muscle of leg	UBERON:0001383	89.15	gold quality
heart left ventricle	UBERON:0002084	89.13	gold quality
transverse colon	UBERON:0001157	88.96	gold quality
left adrenal gland	UBERON:0001234	88.95	gold quality
prostate gland	UBERON:0002367	88.92	gold quality
left adrenal gland cortex	UBERON:0035825	88.84	gold quality
cortex of kidney	UBERON:0001225	88.80	gold quality
body of pancreas	UBERON:0001150	88.78	gold quality
metanephros cortex	UBERON:0010533	88.77	gold quality
embryo	UBERON:0000922	88.55	gold quality
ganglionic eminence	UBERON:0004023	88.55	gold quality
cortical plate	UBERON:0005343	88.34	gold quality
duodenum	UBERON:0002114	88.22	gold quality
fundus of stomach	UBERON:0001160	88.09	gold quality
kidney	UBERON:0002113	87.87	gold quality
adrenal gland	UBERON:0002369	87.65	gold quality
hindlimb stylopod muscle	UBERON:0004252	87.63	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.85
E-MTAB-7303	no	155.77
E-MTAB-6379	no	141.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting LYSET, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-1206	99.30	69.32	1016

Literature-anchored findings (GeneRIF, showing 4)

• Biallelic TMEM251 variants in patients with severe skeletal dysplasia and extreme short stature. (PMID:33252156)
• The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection. (PMID:36074821)
• Lysosomal enzyme trafficking factor LYSET enables nutritional usage of extracellular proteins. (PMID:36074822)
• LYSET/TMEM251- a novel key component of the mannose 6-phosphate pathway. (PMID:36633450)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem251	ENSDARG00000042341
mus_musculus	Lyset	ENSMUSG00000046675
rattus_norvegicus	Lyset	ENSRNOG00000008101

Protein

Protein identifiers

Lysosomal enzyme trafficking factor — Q8N6I4 (reviewed: Q8N6I4)

Alternative names: GNPTAB cleavage and activity factor, Transmembrane protein 251

All UniProt accessions (1): Q8N6I4

UniProt curated annotations — full annotation on UniProt →

Function. Required for mannose-6-phosphate-dependent trafficking of lysosomal enzymes. LYSET bridges GlcNAc-1-phosphate transferase (GNPTAB), to the membrane-bound transcription factor site-1 protease (MBTPS1), thus allowing proteolytic activation of the GNPTAB. GNPTAB is involved in the regulation of M6P-dependent Golgi-to-lysosome trafficking of lysosomal enzymes. LYSET is thus an essential factor for maturation and delivery of lysosomal hydrolases. (Microbial infection) Essential for infection by muliple viruses, including SARS-CoV-2, that utilize activated cathepsins for entry after M6P-dependent lysosomal transport.

Subunit / interactions. Interacts with GNPTAB; this interaction is important for proper localization of GNPTAB in Golgi stacks. Interacts with MBTPS1.

Subcellular location. Golgi apparatus membrane.

Disease relevance. Dysostosis multiplex, Ain-Naz type (DMAN) [MIM:619345] An autosomal recessive, severe skeletal disease characterized by features of dysostosis multiplex, severe short stature, coarse facies with broad nose and prominent lips, protruding abdomens, and progressive skeletal changes causing gradual mobility loss. Death in childhood or early adulthood may occur. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the LYSET family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8N6I4-1	1	yes
Q8N6I4-2	2
Q8N6I4-3	3

RefSeq proteins (2): NP_001092091, NP_056491 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028024	LYSET	Family

Pfam: PF15190

UniProt features (11 total): mutagenesis site 3, transmembrane region 2, splice variant 2, sequence variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N6I4-F1	63.23	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (3):

Position	Phenotype
86	rescues the lysosomal trafficking defect in lyset-deficient cells.
136	rescues the lysosomal trafficking defect in lyset-deficient cells.
150	rescues the lysosomal trafficking defect in lyset-deficient cells.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 179 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_LYSOSOMAL_TRANSPORT, GOBP_VACUOLE_ORGANIZATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, GOBP_PROTEIN_TARGETING, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_VACUOLAR_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, GOBP_PROTEIN_LOCALIZATION_TO_LYSOSOME, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_PROTEIN_LOCALIZATION_TO_VACUOLE, GOBP_REGULATION_OF_PROTEIN_STABILITY, SCHLOSSER_SERUM_RESPONSE_DN

GO Biological Process (7): protein targeting to lysosome (GO:0006622), lysosome organization (GO:0007040), lysosomal transport (GO:0007041), response to virus (GO:0009615), protein catabolic process (GO:0030163), regulation of protein stability (GO:0031647), regulation of vesicle-mediated transport (GO:0060627)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), Golgi cisterna (GO:0031985), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein targeting to vacuole	1
lysosomal transport	1
protein localization to lysosome	1
lytic vacuole organization	1
vacuolar transport	1
response to other organism	1
macromolecule catabolic process	1
protein metabolic process	1
regulation of biological quality	1
vesicle-mediated transport	1
regulation of cellular process	1
regulation of transport	1
binding	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
Golgi stack	1
Golgi apparatus subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

266 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LYSET	PWWP2B	Q6NUJ5	607
LYSET	TAF5L	O75529	521
LYSET	KRTAP4-8	Q9BYQ9	492
LYSET	TMEM41B	Q5BJD5	474
LYSET	ACP1	P24666	473
LYSET	ZMYM2	Q9UBW7	471
LYSET	KLHL42	Q9P2K6	394
LYSET	DALRD3	Q5D0E6	380
LYSET	WDR81	Q562E7	376
LYSET	NAGPA	Q9UK23	375
LYSET	WDR91	A4D1P6	375
LYSET	YPEL1	O60688	368
LYSET	VPS37A	Q8NEZ2	365
LYSET	BORCS8	Q96FH0	365
LYSET	SCAF4	O95104	359

IntAct

2 interactions, top by confidence:

A	B	Type	Score
TMED10	PGRMC1	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): TMEM251 (Negative Genetic), TMEM251 (Phenotypic Enhancement), TMEM251 (Affinity Capture-MS), TMEM251 (Affinity Capture-Western), GNPTAB (Affinity Capture-Western), GNPTG (Co-localization), GNPTAB (Co-localization)

ESM2 similar proteins: A0A7H0DNA7, A0A8I3NQW8, B2RWJ3, C4QVD6, C5DQY5, C7Z504, D1ZRK4, E9EM69, F1LXS7, F5HDD0, F8RT80, O36388, O48670, O94592, P0C655, P20987, P33835, P36707, Q04684, Q09366, Q09714, Q09952, Q09993, Q197D8, Q1KZ54, Q1L864, Q21642, Q28IL7, Q2H3I7, Q2M2T6, Q54U35, Q5M7C7, Q5M9B7, Q5XJX0, Q64919, Q6GNY6, Q6NVQ1, Q6Q7K0, Q6QA74, Q6ZWX0

Diamond homologs: F1LXS7, Q2HJ69, Q5HZT8, Q5TZA3, Q5ZLR7, Q66J17, Q6GLZ9, Q6QA74, Q8BH26, Q8N6I4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	24
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
1120020	NM_001098621.4(LYSET):c.115C>T (p.Arg39Trp)	Pathogenic
1120021	NM_001098621.4(LYSET):c.197dup (p.Tyr66Ter)	Likely pathogenic
807354	NM_001098621.4(LYSET):c.216dup (p.His73fs)	Likely pathogenic

SpliceAI

384 predictions. Top by Δscore:

Variant	Effect	Δscore
14:93185029:G:GT	donor_gain	0.9900
14:93185030:A:T	donor_gain	0.9900
14:93186251:A:AG	acceptor_gain	0.9900
14:93186255:TGAA:T	acceptor_loss	0.9900
14:93186256:GAAG:G	acceptor_loss	0.9900
14:93186258:A:AC	acceptor_loss	0.9900
14:93186430:G:GT	donor_gain	0.9900
14:93186453:A:T	donor_gain	0.9900
14:93186457:C:G	donor_gain	0.9900
14:93186762:G:GT	donor_gain	0.9900
14:93185028:GGAAG:G	donor_gain	0.9800
14:93185030:AAGGT:A	donor_loss	0.9800
14:93185031:AGG:A	donor_loss	0.9800
14:93185032:GGTGA:G	donor_loss	0.9800
14:93185033:GT:G	donor_loss	0.9800
14:93185034:T:A	donor_loss	0.9800
14:93185467:G:GT	donor_gain	0.9800
14:93185486:G:GG	donor_gain	0.9800
14:93186255:T:TA	acceptor_gain	0.9800
14:93186258:A:AG	acceptor_gain	0.9800
14:93186259:G:GG	acceptor_gain	0.9800
14:93186431:A:T	donor_gain	0.9800
14:93186252:A:G	acceptor_gain	0.9700
14:93186258:AG:A	acceptor_gain	0.9700
14:93186259:GG:G	acceptor_gain	0.9700
14:93185033:GTGAG:G	donor_loss	0.9600
14:93185482:CATT:C	donor_gain	0.9600
14:93186251:AATTT:A	acceptor_gain	0.9600
14:93185433:C:G	donor_gain	0.9500
14:93185484:TT:T	donor_gain	0.9500

AlphaMissense

1095 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000116037 (14:93185023 G>C), RS1001228668 (14:93187353 G>A), RS1001434329 (14:93183483 A>G), RS1001484907 (14:93183908 C>T), RS1003021095 (14:93187667 T>A), RS1004292159 (14:93187544 A>G), RS1004788104 (14:93184405 C>T), RS1005153871 (14:93187741 C>T), RS1005566874 (14:93186082 G>C), RS1006076180 (14:93185743 T>G), RS1007087425 (14:93185077 C>T), RS1007491973 (14:93186304 G>A), RS1008486268 (14:93184468 C>G), RS1008582673 (14:93184721 G>A), RS1009207508 (14:93185342 C>T)

Disease associations

OMIM: gene MIM:619332 | disease phenotypes: MIM:619345

GenCC curated gene-disease

Disease	Classification	Inheritance
dysostosis multiplex, Ain-Naz type	Strong	Autosomal recessive

Mondo (2): dysostosis multiplex, Ain-Naz type (MONDO:0859156), intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST004823_4	Cognitive function	3.000000e-06
GCST005951_7	Body mass index	4.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008354	cognitive function measurement
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
dicrotophos	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
trichostatin A	affects expression	1
arsenite	affects binding, increases reaction	1
abrine	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Doxorubicin	increases expression	1
Progesterone	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	increases expression, decreases methylation	1
Cyclosporine	increases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	affects expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2M4	HAP1 TMEM251 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders